The video version of this podcast can be found here: · https://youtu.be/Od1QDebGbBQThis episode makes reference to guidelines produced by the "National Institute for Health and Care Excellence" in the UK, also referred to as "NICE". The content on this channel reflects my professional interpretation/summary of the guidance and I am in no way affiliated with, employed by or funded/sponsored by NICE.NICE stands for "National Institute for Health and Care Excellence" and is an independent organization within the UK healthcare system that produces evidence-based guidelines and recommendations to help healthcare professionals deliver the best possible care to patients, particularly within the NHS (National Health Service) by assessing new health technologies and treatments and determining their cost-effectiveness; essentially guiding best practices for patient care across the country.My name is Fernando Florido and I am a General Practitioner in the United Kingdom. In this episode I go through new and updated recommendations published in December 2024 by the National Institute for Health and Care Excellence (NICE), focusing on those that are relevant to Primary Care only. I am not giving medical advice; this video is intended for health care professionals, it is only my summary and my interpretation of the guidelines and you must use your clinical judgement. Disclaimer:The Video Content on this channel is for educational purposes and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or seen on this YouTube channel. The statements made throughout this video are not to be used or relied on to diagnose, treat, cure or prevent health conditions. In addition, transmission of this Content is not intended to create, and receipt by you does not constitute, a physician-patient relationship with Dr Fernando Florido, his employees, agents, independent contractors, or anyone acting on behalf of Dr Fernando Florido. Intro / outro music: Track: Halfway Through — Broke In Summer [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/aBGk6aJM3IU Free Download / Stream: https://alplus.io/halfway-through There is a podcast version of this and other videos that you can access here: Primary Care guidelines podcast: · Redcircle: https://redcircle.com/shows/primary-care-guidelines· Spotify: https://open.spotify.com/show/5BmqS0Ol16oQ7Kr1WYzupK· Apple podcasts: https://podcasts.apple.com/gb/podcast/primary-care-guidelines/id1608821148 There is a YouTube version of this and other videos that you can access here: The Practical GP YouTube Channel: https://youtube.com/@practicalgp?si=ecJGF5QCuMLQ6hrk The Full NICE News bulletin for December 2024 can be found here:· https://www.nice.org.uk/guidance/published?from=2024-12-01&to=2024-12-31&ndt=Guidance&ndt=Quality+standard The links to the guidance covered in this episode can be found here: Tirzepatide for managing overweight and obesity: · https://www.nice.org.uk/guidance/ta1026 Urinary tract infection (recurrent): antimicrobial prescribing: · https://www.nice.org.uk/guidance/ng112 Meningitis (bacterial) and meningococcal disease: · https://www.nice.org.uk/guidance/qs19 TranscriptIf you are listening to this podcast on YouTube, for a better experience, switch to the video version. The link is in the top right corner of the video and in the episode description.Hello and welcome, I am Fernando, a GP in the UK. Today, we are looking at the NICE updates published in December 2024, focusing on what is relevant in Primary Care only. In today’s episode, we’re covering two important clinical topics:Tirzepatide for managing overweight and obesity, andAntimicrobial prescribing for recurrent UTIs.But before we jump into the details, let’s take a moment to highlight a game-changing development: the new NICE technology appraisal on Tirzepatide.For many GPs, the surge in patient requests for Ozempic (or semaglutide) to manage obesity has been a challenging situation, especially as NICE does not recommend its use in primary care for this purpose. Could Tirzepatide mark the end of the GP Ozempic nightmare?Right, let’s find out!In the technology appraisal assessing Tirzepatide for overweight and obesity NICE has recommended it as an option for adults, alongside diet and exercise only if they have:an initial BMI of at least 35 kg/m2 reduced to 32.5 for people from Asian, Chinese, Middle Eastern, and Black African or African-Caribbean ethnic backgrounds. andat least 1 weight-related comorbidity. Examples would be, for example, hypertension, dyslipidaemia, ...
